Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $47.89 Average Target Price from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been assigned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $47.89.

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They issued a “neutral” rating and a $31.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 11th. Morgan Stanley cut their price objective on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating on the stock in a research report on Monday, May 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Thursday, June 20th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, June 26th.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock opened at $26.05 on Tuesday. The business has a 50-day moving average of $24.46 and a 200 day moving average of $28.36. The stock has a market capitalization of $3.24 billion, a PE ratio of -6.13 and a beta of 0.94. Arrowhead Pharmaceuticals has a 1-year low of $20.67 and a 1-year high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. During the same period in the previous year, the business posted $0.45 EPS. Arrowhead Pharmaceuticals’s quarterly revenue was down 100.0% on a year-over-year basis. Analysts anticipate that Arrowhead Pharmaceuticals will post -3.05 EPS for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the completion of the transaction, the director now directly owns 30,205 shares of the company’s stock, valued at approximately $704,078.55. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 4.50% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ARWR. FMR LLC increased its position in Arrowhead Pharmaceuticals by 58.2% during the third quarter. FMR LLC now owns 4,308,903 shares of the biotechnology company’s stock valued at $115,780,000 after acquiring an additional 1,584,425 shares during the last quarter. Invesco Ltd. increased its holdings in Arrowhead Pharmaceuticals by 9.6% in the 3rd quarter. Invesco Ltd. now owns 2,443,038 shares of the biotechnology company’s stock worth $65,644,000 after acquiring an additional 214,618 shares in the last quarter. Profund Advisors LLC increased its holdings in Arrowhead Pharmaceuticals by 14.5% in the 3rd quarter. Profund Advisors LLC now owns 53,917 shares of the biotechnology company’s stock worth $1,449,000 after acquiring an additional 6,830 shares in the last quarter. O Shaughnessy Asset Management LLC purchased a new position in Arrowhead Pharmaceuticals during the third quarter valued at approximately $257,000. Finally, Qube Research & Technologies Ltd boosted its position in shares of Arrowhead Pharmaceuticals by 98.2% in the third quarter. Qube Research & Technologies Ltd now owns 71,558 shares of the biotechnology company’s stock worth $1,923,000 after purchasing an additional 35,463 shares during the period. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.